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The disk screening methods for extended-spectrum -lactamase-producing strains were evaluated. The
confirmatory work is reduced significantly in settings such as those in this study, by changing the cefpodoxime
breakpoint to <20 mm and by not testing cefoxitin-resistant isolates. Cefotaxime and ceftazidime disk
screening is reliable, and the laboratory-prepared cefotaxime- and ceftazidime-clavulanic acid disks are stable
at 20°C for 12 weeks.
The detection of extended-spectrum -lactamase (ESBL)-
producing strains is important for optimal therapy of infected
patients. The screening and confirmation of ESBL-producing
isolates using the methods of the NCCLS (12) are easily per-
formed. A survey in Korea suggested a high prevalence of
ESBL-producing isolates (7), and with the increase of cefpo-
doxime disk screening-positive isolates, laboratories are con-
fronted with an increasing burden of confirming results. Par-
ticularly, the almost daily preparation of clavulanic acid solution-
supplemented ceftazidime (ceftazidime-clavulanic acid) and
cefotaxime (cefotaxime-clavulanic acid) disks requires time.
Isolates producing certain ESBL types with low hydrolytic
activity (4) are difficult to detect (14). In Korea, only TEM-52-,
SHV-2a-, and SHV-12-type ESBLs have been reported (6, 13),
and the cefpodoxime disk screening-positive isolates have of-
ten been ESBL nonproducers (Y. Chong, J. K. Lim, D. Yong,
J. W. Yum, K. Lee, R. Okamoto, and M. Inoue, Abstr. 40th
Intersci. Conf. Antimicrob. Agents Chemother., abstr. 1608,
2000). In this study, we evaluated the efficiency of NCCLS disk
screening methods in Korea and determined the stability of the
laboratory-prepared cefotaxime- and ceftazidime-clavulanic
acid disks in storage.
TABLE 1. Cefpodoxime disk zone diameter distribution for ESBL-producing and -nonproducing isolates
Cefpodoxime zone diam (mm)
No. of isolates for species, cefoxitin susceptibility, and ESBL statusa
E. coli (n  256) K. pneumoniae (n  109)
Cefoxitin S (I) Cefoxitin R Cefoxitin S (I) Cefoxitin R
ESBL positive
(n  20)
ESBL negative
(n  174)
ESBL positive
(n  6)
ESBL negative
(n  56)
ESBL positive
(n  33)
ESBL negative
(n  58)
ESBL positive
(n  8)
ESBL negative
(n  10)
13 14 (1) 0 (1) 5 53 31 (1) 1 (1) 8 8
13–14 2 2 (1) 1
15–16 1 1 1
17–18 2 5 2
19–20 4
21–22 17 (2) 2 2
23–24 38 (1) 10 (1)
25–26 42 14 (1)
27–28 31 10
28 30 18
No. (%) screening positive 20 (7.8) 32 (12.5) 6 (2.3) 56 (21.9) 33 (30.2) 4 (3.7) 8 (7.3) 10 (9.2)
a Boldface indicates isolates which were cefpodoxime-screening positive. Abbreviations: S (I), susceptible (intermediate); R, resistant.
* Corresponding author. Mailing address: Department of Clinical
Pathology, Yonsei University College of Medicine, 134 Shinchon-
dong, Seodaemun-ku, Seoul, 120-752, Korea. Phone: 82-2-361-5866.
Fax: 82-2-313-0908. E-mail: whonetkor@yumc.yonsei.ac.kr.
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Isolates of Escherichia coli and Klebsiella pneumoniae were
collected in 1999 in Korea: in phase I, from a tertiary-care
hospital, and in phase II, from 28 hospitals with various bed
capacities and locations. Antimicrobial susceptibility was
tested by the NCCLS disk diffusion method (11) using Muel-
ler-Hinton agar plates and antimicrobial disks (Becton Dick-
inson Microbiology Systems, Sparks, Md.). ESBL production
was screened using cefpodoxime disks (12). To confirm ESBL
production, the isolates were tested by double-disk synergy
tests (8) using an amoxicillin-clavulanic acid disk plus cefo-
taxime, ceftazidime, and aztreonam disks and by comparing
the MICs (10, 12) of cefotaxime and ceftazidime with or with-
out 4 g of clavulanic acid (Smith-Kline Beecham, Worthing,
United Kingdom) per ml.
Some characteristics of ESBLs were determined using
transconjugants obtained by agar mating (2) using recipient E.
coli RG 176 (Nalr), RG 488 (Rifr) (kindly provided by Dong
Taek Cho, College of Medicine, Kyungpook National Univer-
sity, Taegu, Korea), or J53 (Azr) (kindly provided by Chik
Hyun Pai, College of Medicine, Ulsan University, Ulsan, Ko-
rea). PCR was performed using heat-extracted templates as
described previously (5). The isoelectric point (pI) of -lacta-
mase (9) was determined by electrophoresis of the cell sonicate
using a pH 3 to 10 gel and a ThermoFlow unit (Novex Exper-
imental Technology, San Diego, Calif.) and staining with 0.7
mg of nitrocefin (Unipath, Basingstoke, United Kingdom) per
ml. The cefotaxime- and ceftazidime-clavulanic acid disks, pre-
pared as recommended by the NCCLS (12), were placed in
vials with desiccant and stored at 4° and 20°C, and the inhi-
bition zone diameters were determined using ESBL-producing
strains: K. pneumoniae ATCC 700603, two clinical isolates of
K. pneumoniae, and one clinical isolate of E. coli.
In the phase I study, 114 of 256 (44.5%) E. coli and 55 of 109
(50.5%) K. pneumoniae isolates were cefpodoxime disk screen-
ing positive (Table 1). Among them, 62 (24.2%) E. coli and 18
(16.5%) K. pneumoniae isolates were cefoxitin resistant, and
among the cefoxitin-susceptible or -intermediate isolates, only
20 (7.8%) E. coli and 33 (30.2%) K. pneumoniae isolates were
ESBL positive. ESBL-positive isolates of E. coli and K. pneu-
moniae showed cefpodoxime zone diameters of 18 and 14
mm, respectively.
Efficiencies of screening of ESBL-producing isolates with
disks of aztreonam, cefotaxime, and ceftazidime were com-
pared (Table 2). All of the three antimicrobial disks detected
all ESBL-producing isolates, but two and four isolates of E. coli
were just within the breakpoint of aztreonam (27 mm) and
ceftazidime (22 mm), respectively. Among the cefoxitin-non-
resistant and ESBL-negative isolates, only 23 (13.2%), 22
(12.6%), and 12 (6.9%) E. coli isolates and 17 (29.3%), 20
(34.5%), and 3 (5.2%) K. pneumoniae isolates were positive by
screening with aztreonam, cefotaxime, and ceftazidime, re-
spectively.
In the phase II study (Table 3), the proportion of ESBL-
positive isolates of E. coli was relatively higher (35.6%) than
that in the phase I hospital, because of lower prevalence of
cefoxitin-resistant isolates, but for K. pneumoniae, the rates
were fairly similar in the two phases. The MICs of cefotaxime
or ceftazidime were 2 g/ml for six and two ESBL-producing
isolates of E. coli and K. pneumoniae, respectively (data not
shown), but all of them were positive by screening with cefpo-
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doxime, cefotaxime, and ceftazidime disks. The blaTEM and/or
blaSHV sequence was detected in all ESBL-producing transcon-
jugants (Table 4), and their -lactamases had a pI of 6.0, 7.6, or
8.2, suggesting that they were TEM-52, SHV-2a, or SHV-12
type, respectively. The mean MIC of ceftazidime was higher
for isolates with a pI 8.2 -lactamase.
The inhibition zone diameter produced by the cefotaxime-
and ceftazidime-clavulanic acid disks did not change signifi-
cantly after 1 week at 4°C or after 12 weeks at20°C (Table 5).
In the phase I study, 12.5% of E. coli isolates were cefpo-
doxime disk screening positive but ESBL negative. By reducing
the screening breakpoint by 2 mm to 20 mm, the false-
positive rate decreased by 59.4% in E. coli, but this did not
influence the result significantly in K. pneumoniae (Table 1). In
a U.S. study, 42.2% of cefpodoxime screening-positive E. coli
isolates were ESBL nonproducers (F. C. Tenover, P. Raney,
P. P. Williams, K. L. Brittain, C. D. Steward, S. K. Fridkin,
R. P. Gaynes, and J. E. McGowan, Jr., Abstr. 40th Intersci.
Conf. Antimicrob. Agents Chemother., abstr. 1606, 2000),
which indicates the feasibility of eliminating unnecessary work
by adjusting breakpoints in other countries, too.
CMY-1-producing strains continue to be prevalent in Korea
(1), and AmpC -lactamases have been reported worldwide,
including the United States (3). It may not be significant to
detect ESBL producers among cefoxitin-resistant isolates, as
AmpC -lactamase producers are resistant to all -lactams
except carbapenem, temocillin, and mecillinam (8). If so,
54.4% of cefpodoxime screening-positive E. coli isolates in the
phase I study did not require a confirmatory test (Table 3). The
reduction was only 10.2% in phase II hospitals, but such iso-
lates may increase in the near future. In a U.S. study, 16.3% of
cefpodoxime screening-positive E. coli isolates were ESBL
nonproducers and were possibly AmpC -lactamase producers
(Tenover et al., 40th ICAAC).
Additional testing of cefpodoxime susceptibility for only E.
coli and Klebsiella isolates may hinder laboratory workflow, as
the species identification and susceptibility testing are usually
performed simultaneously. If cefotaxime, ceftazidime, or az-
treonam susceptibility is reliable for screening ESBL produc-
ers, its use can help streamline laboratory workflow, as the
drugs are usually used for susceptibility testing of all aerobic
gram-negative bacilli. In this study, some isolates were inhib-
ited by 2 g of cefotaxime or ceftazidime per ml, which is much
lower than the 16 g of ceftazidime per ml in a U.S. study
(Tenover et al., 40th ICAAC), but all were screening test
positive with cefotaxime and ceftazidime disks. However, two
and four ESBL-producing E. coli isolates were just within the
breakpoints of aztreonam and ceftazidime, respectively, sug-
gesting that the current breakpoints may not be high enough in
Korea.
In the past, preparation of screening disks has been a lim-
iting factor in routine testing for ESBL-producing enteric or-
ganisms. The process was time-consuming for a busy labora-
tory, and the long-term stability of the disks was unknown.
Recently, such disks have been reported to be stable for at
least 14 days at20°C (15), and in this study we have extended
that observation for up to 12 weeks at 20°C. Although cla-
vulanic acid-containing ceftazidime and cefotaxime disks have
TABLE 3. Efficiency of cefpodoxime disk screening test for ESBL-producing isolates in a tertiary-care hospital and in other hospitalsa
Cefpodoxime
zone diam
(mm)
No. of isolates for species, cefoxitin susceptibility, and study phase
E. coli (n  232) K. pneumoniae (n  132)
Cefoxitin S/I Cefoxitin R Cefoxitin S/I Cefoxitin R
Phase I Phase II Phase I Phase II Phase I Phase II Phase I Phase II
10 11 33 57 9 25 34 15 12
11–12 4 7 1 3 7 6 1 3
13–14 2 2 1 1
15–16 1 2
17–18 2 2 2
Total (%) 20 (17.5) 42 (35.6) 62 (54.4) 12 (10.2) 33 (62.3) 41 (51.9) 18 (34.0) 15 (19.0)
a Isolates that were cefoxitin susceptible or intermediate were all positive for ESBL production. Results for cefoxitin-susceptible or -intermediate isolates that were
negative for ESBL production are not shown. The numbers of isolates tested for each phase are as follows: phase I, 114 of E. coli and 55 of K. pneumoniae, and phase
II, 118 of E. coli and 79 of K. pneumoniae. S/I, susceptible or intermediate; R, resistant.
TABLE 4. Comparison of MICs of expanded-spectrum cephalosporin and aztreonam for transconjugants by possession
of TEM and SHV genes and pI patterns of -lactamase
Gene(s) detected
No. of isolates -Lactamase with (pI)a: Mean MIC (g/ml) of drugb:
E. coli K. pneumoniae Total (%) 5.4 6.0 7.6 8.2 CAZ CTX CRO ATM
blaTEM 6 4 10 (20.0)   53 18 10 5
blaSHV 2 2 4 (8.0)  84 44 38 11
blaSHV 7 7 (14.0)  144 8 7 36
blaSHV 7 7 (14.0)  237 42 33 96
blaTEM  blaSHV 7 15 22 (44.0)   151 11 10 47
a Possible -lactamase types were TEM-52 (pI 6.0), SHV-2a (pI 7.6), and SHV-12 (pI 8.2).
b Abbreviations: CAZ, ceftazidime; CTX, cefotaxime; CRO, ceftriaxone; AZT, aztreonam.
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become commercially available, they may be too expensive for
some laboratories to purchase and, hence, those laboratories
may still have to prepare their own. The method described
herein enables laboratories to prepare large batches of disks at
one time and store them for several months. By using prepre-
pared and stored disks, laboratories will have a cost- and time-
saving alternative for the routine confirmation of ESBL-pro-
ducing isolates.
This work was supported in part by the BK21 Project for Medical
Sciences, Yonsei University, in 2001.
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CAZ
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CTX
CTX-CLA
CAZ
CAZ-CLA
CAZ
CAZ-CLA
CAZ
CAZ-CLA
4°C 20°C 4°C 20°C 4°C 20°C 4°C 20°C 4°C 20°C
0 13 22 22 18 23 23 16 25 25 10 25 25 6 25 25
1 14 21 23 20 23 23 17 25 25 11 25 25 6 24 24
2 14 21 23 20 23 23 17 25 25 12 22 25 6 23 25
3 14 22 22 18 23 23 17 23 23 12 22 25 6 21 23
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cefotaxime; CTX-CLA, cefotaxime-clavulanic acid.
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